Tuberous Sclerosis and Fulminant Lupus in a Young Woman

被引:31
作者
Singh, Namrata [1 ]
Birkenbach, Mark [1 ]
Caza, Tiffany [2 ]
Perl, Andras [2 ]
Cohen, Philip L. [1 ]
机构
[1] Temple Univ, Sch Med, Div Rheumatol, Philadelphia, PA 19122 USA
[2] SUNY Syracuse, Coll Med, Div Rheumatol, Syracuse, NY USA
关键词
tuberous sclerosis; systemic lupus erythematosus; rapamycin; mTOR; RAPAMYCIN; NEPHRITIS; INHIBITION; ACTIVATION; PATHWAY; CELLS;
D O I
10.1097/RHU.0b013e318289c033
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Tuberous sclerosis is an autosomal dominant disorder characterized by involvement of skin, nervous system, kidneys, and lungs. It results from mutations in 1 of 2 genes: TSC1 (encoding hamartin) or TSC2 (encoding tuberin), leading to dysregulation and activation of the mammalian target of rapamycin (mTOR) pathway. Constitutive activation of mTOR signaling has recently been reported in systemic lupus erythematosus (SLE), and inhibition of this pathway may benefit patients with SLE nephritis. We report a case of a young woman with tuberous sclerosis who developed fulminant SLE, with lower extremity edema, massive proteinuria, and class IV lupus glomerulonephritis. She died despite treatment with high-dose steroids, plasmapheresis, and cyclophosphamide. Although there are no prior reports of coexistence of these 2 rare diseases, this case is of considerable interest because of the possibility that activation of mTOR by the TSC mutations may have led to activation of the immune system and the development of unusually severe SLE.
引用
收藏
页码:134 / 137
页数:4
相关论文
共 13 条
[1]
PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus [J].
Barber, DF ;
Bartolomé, A ;
Hernandez, C ;
Flores, JM ;
Redondo, C ;
Fernandez-Arias, C ;
Camps, M ;
Ruckle, T ;
Schwarz, MK ;
Rodríguez, S ;
Martinez-A, C ;
Balomenos, D ;
Rommel, C ;
Carrera, AC .
NATURE MEDICINE, 2005, 11 (09) :933-935
[2]
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells [J].
Battaglia, M ;
Stabilini, A ;
Roncarolo, MG .
BLOOD, 2005, 105 (12) :4743-4748
[3]
Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3) K-mTOR-p70S6K pathway [J].
Cao, Weiping ;
Manicassamy, Santhakumar ;
Tang, Hua ;
Kasturi, Sudhir Pai ;
Pirani, Ali ;
Murthy, Niren ;
Pulendran, Bali .
NATURE IMMUNOLOGY, 2008, 9 (10) :1157-1164
[4]
Rapamycin reduces disease activity and normalizes T-Cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. [J].
Fernandez, David ;
Bonilla, Eduardo ;
Mirza, Naureen ;
Niland, Brian ;
Perl, Andras .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :S261-S261
[5]
Fernandez D, 2010, DISCOV MED, V9, P173
[6]
Activation of Mammalian Target of Rapamycin Controls the Loss of TCRζ in Lupus T Cells through HRES-1/Rab4-Regulated Lysosomal Degradation [J].
Fernandez, David R. ;
Telarico, Tiffany ;
Bonilla, Eduardo ;
Li, Qing ;
Banerjee, Sanjay ;
Middleton, Frank A. ;
Phillips, Paul E. ;
Crow, Mary K. ;
Oess, Stefanie ;
Muller-Esterl, Werner ;
Perl, Andras .
JOURNAL OF IMMUNOLOGY, 2009, 182 (04) :2063-2073
[7]
Rapamycin prevents the development of nephritis in lupus-pirone NZH/W F1 mice [J].
Lui, S. L. ;
Yung, S. ;
Tsang, R. ;
Zhang, F. ;
Chan, K. W. ;
Tam, S. ;
Chan, T. M. .
LUPUS, 2008, 17 (04) :305-313
[8]
Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice [J].
Lui, Sing Leung ;
Tsang, Ryan ;
Chan, Kwok Wah ;
Zhang, Florence ;
Tam, Sidney ;
Yung, Susan ;
Chan, Tak Mao .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (09) :2768-2776
[9]
Perl A, 2004, METH MOLEC MED, V102, P87
[10]
Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis [J].
Reddy, Padmalatha S. ;
Legault, Holly M. ;
Sypek, Joseph P. ;
Collins, Mark J. ;
Goad, Elizabeth ;
Goldman, Samuel J. ;
Liu, Wei ;
Murray, Stuart ;
Dorner, Andrew J. ;
O'Toole, Margot .
ARTHRITIS RESEARCH & THERAPY, 2008, 10 (06)